mConsent to Resell iCoreRx Cloud ePrescribing Solution by iCoreConnect
05 August 2024 - 10:30PM
iCoreConnect Inc. (NASDAQ: ICCT) (“iCore” or the “Company”), a
leading cloud-based software and technology company, today
announced a new reseller agreement with mConsent, a leader in
digital patient intake, patient communication and engagement
solutions. Through this partnership, mConsent will now offer
iCoreConnect's premier electronic prescribing software, iCoreRx, as
part of its suite of digital solutions.
This collaboration allows mConsent to expand its offerings by
providing dental practices with iCoreRx, an advanced ePrescribing
software designed to streamline prescription workflows and enhance
patient safety. By integrating iCoreRx into their product lineup,
mConsent can deliver a more comprehensive set of tools to improve
the efficiency and effectiveness of their Patient Engagement
Platform.
"We are excited to partner with mConsent and expand the reach of
iCoreRx," said Robert McDermott, CEO of iCoreConnect. "mConsent's
commitment to innovation and excellence aligns perfectly with our
mission to provide superior software solutions for dental
practices. This partnership will enable us to bring the benefits of
iCoreRx to a wider audience."
iCoreRx is known for its user-friendly interface and secure,
cloud-based platform that simplifies the ePrescribing process. The
software ensures compliance with the latest ePrescribing
regulations and offers features such as real-time drug interaction
checks, automatic updates, and integration with various practice
management systems. By adding iCoreRx to its offerings, mConsent
can help dental professionals reduce errors, save time, and improve
patient outcomes.
"We are thrilled to become a reseller of iCoreRx," said Samad
Syed, CEO of mConsent. "This partnership with iCoreConnect enables
us to offer a robust electronic prescribing solution that
complements our entire suite of patient engagement solutions.
Together, we can provide dental practices with a seamless,
integrated experience that enhances patient care and operational
efficiency."
About iCoreConnect Inc. (NASDAQ: ICCT)
iCoreConnect Inc. is a leading, cloud-based software and
technology company focused on increasing workflow productivity and
practice profitability through its enterprise and healthcare
workflow platform of applications and services. iCoreConnect is
most notably known for its innovation in solving healthcare
business problems. iCoreConnect’s philosophy places a high value on
customer feedback, positioning iCoreConnect to respond to the
market’s needs. iCoreConnect touts a platform of 16 SaaS enterprise
solutions and more than 130 product endorsements with state or
regional healthcare associations across the United States.
About mConsent
mConsent, recognized as INC 5000 fastest growing SaaS platform
for dental practices, is a full-service patient engagement platform
that is currently used by over 5 million patients across the United
States. It is a one-stop-solution for dental practices that want to
automate their operational workflow for a seamless patient
experience. From patient intake to patient communication and
engagement, mConsent places a high level of emphasis on empowering
office staff to move away from administrative activities for a more
patient centric experience. An average practice using mConsent
saves ~$65K/year on administrative costs, cuts down documentation
time by 35% while tripling patient satisfaction and garnering
positive reviews. mConsent’s philosophy is to revolutionize the
dental industry, one practice at a time.
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Although the Company believes that the
expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. The Company has attempted to identify
forward-looking statements by terminology including ‘believes,’
‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’
‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’
‘approximately’ or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including those discussed
under Item 1A. “Risk Factors” in the Company’s most recently filed
Form 10-K filed with the Securities and Exchange Commission (“SEC”)
and updated from time to time in its Form 10-Q filings and in its
other public filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. The Company
undertakes no obligation to update any forward-looking statements
contained in this release to reflect events or circumstances
occurring after its date or to reflect the occurrence of
unanticipated events.
Media Contact:ir@icoreConnect.com 888.810.7706
ext.5
iCoreConnect (NASDAQ:ICCT)
Historical Stock Chart
From Nov 2024 to Dec 2024
iCoreConnect (NASDAQ:ICCT)
Historical Stock Chart
From Dec 2023 to Dec 2024